Literature DB >> 22569896

Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas.

Hiroshi Nishioka1, Naoko Inoshita, Toshiaki Sano, Noriaki Fukuhara, Shozo Yamada.   

Abstract

Clinically nonfunctioning pituitary adenomas (CNFPAs) consist of several histological subtypes, including null cell adenoma (NCA), silent gonadotroph cell adenoma (SGA), silent corticotroph adenoma (SCA), and other silent adenomas (OSA) (i.e., GH, TSH, and prolactin adenomas). To detect possible correlations between MRI findings and the subtypes, we retrospectively studied 390 consecutive patients with CNFPA who underwent surgery between 2008 and 2010. They were classified into three groups: NCA/SGA (313 cases), SCA (39 cases), and OSA (36 cases); in addition there were two unusual cases of plurihormonal adenoma. Three MRI findings were less common in NCA/SGA than in the other groups (P < 0.0001): giant adenoma (>40 mm), marked cavernous sinus invasion (Knosp grade 4), and lobulated configuration of the suprasellar tumor. When these MRI findings were negative in patients older than 40 years old, 91.0% (212/233) were NCA/SGA. These MRI findings were frequently noted despite a low MIB-1 index in SCA. OSA showed a high MIB-1 index and a preponderance in younger patients. In conclusion, although SCA and OSA consisted of only 20% of CNFPAs, their frequency significantly increased when the tumor was large, invasive, and lobulated, and the patient was younger than 40 years old.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569896     DOI: 10.1007/s12022-012-9208-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  24 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Defining the "edge of the envelope": patient selection in treating complex sellar-based neoplasms via transsphenoidal versus open craniotomy.

Authors:  Gabriel Zada; Rose Du; Edward R Laws
Journal:  J Neurosurg       Date:  2010-09-03       Impact factor: 5.115

3.  Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity.

Authors:  Akiko Yoneda; Toshiaki Sano; Shozo Yamada; Abdulkader Obari; Zhi Rong Qian; Elaine Lu Wang; Naoko Inosita; Eiji Kudo
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

4.  Simultaneous combined supra-infrasellar approach for giant/large multilobulated pituitary adenomas.

Authors:  Hiroshi Nishioka; Takayuki Hara; Masaaki Usui; Noriaki Fukuhara; Shozo Yamada
Journal:  World Neurosurg       Date:  2011-11-07       Impact factor: 2.104

5.  Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive?

Authors:  S Yokoyama; H Hirano; K Moroki; M Goto; S Imamura; J I Kuratsu
Journal:  Neurosurgery       Date:  2001-10       Impact factor: 4.654

6.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

7.  Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.

Authors:  Li-Xiong Pan; Zhong-Ping Chen; Yun-Sheng Liu; Ji-Hong Zhao
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 8.  Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.

Authors:  Márta Korbonits; Eivind Carlsen
Journal:  Horm Res       Date:  2009-04-29

9.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

10.  Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas.

Authors:  Edward F Chang; Gabriel Zada; Sang Kim; Kathleen R Lamborn; Alfredo Quinones-Hinojosa; J Blake Tyrrell; Charles B Wilson; Sandeep Kunwar
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

View more
  5 in total

1.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 2.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.

Authors:  Kristin Astrid B Øystese; Olivera Casar-Borota; Jon Berg-Johnsen; Jens Petter Berg; Jens Bollerslev
Journal:  Endocrine       Date:  2022-06-08       Impact factor: 3.925

4.  Imaging of Resected Nonfunctioning Pituitary Adenomas: The Cost of Surveillance.

Authors:  Heather M Kistka; Rebecca A Kasl; Arash Nayeri; Andrea L Utz; Kyle D Weaver; Lola B Chambless
Journal:  J Neurol Surg B Skull Base       Date:  2015-05-08

5.  MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.

Authors:  Shinsuke Uraki; Hiroyuki Ariyasu; Asako Doi; Ken Takeshima; Shuhei Morita; Hidefumi Inaba; Hiroto Furuta; Noriaki Fukuhara; Naoko Inoshita; Hiroshi Nishioka; Naoyuki Nakao; Shozo Yamada; Takashi Akamizu
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.